Form 8-K - Current report:
SEC Accession No. 0001829126-26-001911
Filing Date
2026-03-04
Accepted
2026-03-04 09:16:52
Documents
14
Period of Report
2026-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K kalabio_8k.htm   iXBRL 8-K 40941
2 EXHIBIT 10.1 kalabio_ex10-1.htm EX-10.1 285277
3 EXHIBIT 99.1 kalabio_ex99-1.htm EX-99.1 70134
  Complete submission text file 0001829126-26-001911.txt   617246

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE kala-20260303.xsd EX-101.SCH 2990
5 XBRL LABEL FILE kala-20260303_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE kala-20260303_pre.xml EX-101.PRE 22342
16 EXTRACTED XBRL INSTANCE DOCUMENT kalabio_8k_htm.xml XML 3095
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 26719062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)